Zynerba pharmaceuticals, inc. (ZYNE)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Revenue

-

-

-

-

-

86

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

7

49

199

15

14

74

525

64

146

Operating expenses:
Research and development

6,882

-

-

8,223

6,306

-

-

-

-

5,828

5,753

5,732

5,491

4,904

4,504

4,807

2,568

3,309

2,271

1,010

853

815

932

367

285

General and administrative

3,916

3,958

3,530

3,287

3,159

3,256

3,125

3,436

3,420

2,376

2,795

2,632

2,211

1,780

1,493

1,476

1,680

2,156

1,922

631

653

662

2,107

1,206

99

Total operating expenses

10,799

11,416

1,926

11,511

9,466

8,132

7,985

11,969

12,396

8,204

8,549

8,365

7,703

6,684

5,997

6,283

4,249

5,465

4,194

1,642

1,507

1,478

3,040

1,573

385

Loss from operations

-10,799

-11,416

-1,926

-11,511

-9,466

-8,046

-7,985

-11,969

-12,396

-8,204

-8,549

-8,365

-7,703

-6,684

-5,997

-6,283

-4,241

-5,416

-3,995

-1,627

-1,492

-1,404

-2,514

-1,509

-239

Other income (expense):
Interest income

201

295

436

439

350

321

278

186

175

156

161

124

76

26

22

18

12

-

-

-

-

-

-

-

-

Interest income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4

1

0

0

0

-0

-0

-1

Foreign exchange loss

-1,740

406

-457

-63

-31

-65

-99

-223

-85

-70

76

-82

367

-139

-6

-20

-23

-

-

-

-

-

-

-

-

Loss on disposal of equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-99

-

-

-

-

-

-

-

-

-

-

-

Total other income

-1,538

701

-20

375

319

255

178

-37

89

85

238

42

444

-211

16

-2

-10

-

1

-

-

-

-

-

-

Loss before income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-6,896

-5,981

-6,285

-4,252

-5,411

-

-

-

-

-

-

-

Total other income (expense)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

Loss before income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-3,993

-1,626

-1,491

-

-

-

-

Income tax benefit

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-56

28

-27

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-3,993

-1,626

-1,491

-1,404

-2,515

-1,509

-240

Accretion of redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

87

Net loss

-12,337

-10,714

-1,946

-11,135

-9,147

-7,790

-7,807

-12,007

-12,306

-8,118

-8,311

-8,323

-7,259

-6,896

-5,981

-6,229

-4,281

5,439

-

-

-

-1,404

-2,515

-1,509

-328

Net loss per share basic and diluted

-0.53

-0.46

-0.08

-0.50

-0.47

-0.44

-0.47

-0.89

-0.91

-0.60

-0.63

-0.64

-0.60

-0.71

-0.67

-0.70

-0.49

-0.62

-0.66

-1.12

-1.03

-0.96

-2.64

-2.29

-0.67

Basic and diluted weighted average shares outstanding

23,399

23,191

23,186

22,116

19,452

17,616

16,587

13,504

13,467

13,423

13,098

13,052

12,067

9,678

8,912

8,860

8,823

8,787

6,045

1,449

1,449

1,462

954

659

490